Patents Assigned to ICB International, Inc.
  • Patent number: 10738109
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: August 11, 2020
    Assignee: ICB INTERNATIONAL, INC.
    Inventors: Ram S. Bhatt, Rishi S. Bhatt
  • Patent number: 10112988
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: October 30, 2018
    Assignee: ICB INTERNATIONAL, INC.
    Inventors: Ram S. Bhatt, Rishi Bhatt
  • Patent number: 10112987
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: October 30, 2018
    Assignee: ICB INTERNATIONAL, INC.
    Inventors: Ram S. Bhatt, Rishi Bhatt
  • Publication number: 20140193834
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain, bound to one or more constant domains.
    Type: Application
    Filed: June 13, 2013
    Publication date: July 10, 2014
    Applicant: ICB International, Inc.
    Inventors: Ram S. Bhatt, Rishi Bhatt
  • Publication number: 20130177568
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
    Type: Application
    Filed: January 8, 2013
    Publication date: July 11, 2013
    Applicant: ICB International, Inc.
    Inventor: ICB International, Inc.